79 related articles for article (PubMed ID: 8021743)
21. Clinical trials referral resource. Prostate cancer II.
Cheson BD; Phillips PH; Kaplan RS
Oncology (Williston Park); 1995 Jan; 9(1):50, 55. PubMed ID: 7718441
[No Abstract] [Full Text] [Related]
22. Anaphylactoid reaction with suramin.
Thibault A; Figg WD; Cooper MR; Prindiville SA; Sartor AO; Headlee DJ; Myers CE
Pharmacotherapy; 1993; 13(6):656-7. PubMed ID: 8302692
[TBL] [Abstract][Full Text] [Related]
23. [Cutaneous drug reaction caused by suramin in 4 patients with metastatic prostate cancer].
Wichterich K; Tebbe B; Handke A; Dieckmann KP; Gollnick H
Hautarzt; 1994 Feb; 45(2):84-7. PubMed ID: 8150636
[TBL] [Abstract][Full Text] [Related]
24. Suramin-induced skin reactions.
O'Donnell BP; Dawson NA; Weiss RB; Myers CE; James WD
Arch Dermatol; 1992 Jan; 128(1):75-9. PubMed ID: 1531404
[TBL] [Abstract][Full Text] [Related]
25. Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.
George S; Dreicer R; Au JJ; Shen T; Rini BI; Roman S; Cooney MM; Mekhail T; Elson P; Wientjes GM; Ganapathi R; Bukowski RM
Clin Genitourin Cancer; 2008 Sep; 6(2):79-85. PubMed ID: 18824429
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.
Lawrence JB; Conover CA; Haddad TC; Ingle JN; Reid JM; Ames MM; Suman VJ; Marks RS; Erlichman C; Hartmann LC
Clin Cancer Res; 1997 Oct; 3(10):1713-20. PubMed ID: 9815555
[TBL] [Abstract][Full Text] [Related]
27. Use of adaptive control with feedback to individualize suramin dosing.
Scher HI; Jodrell DI; Iversen JM; Curley T; Tong W; Egorin MJ; Forrest A
Cancer Res; 1992 Jan; 52(1):64-70. PubMed ID: 1727387
[TBL] [Abstract][Full Text] [Related]
28. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.
Safarinejad MR
Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993
[TBL] [Abstract][Full Text] [Related]
29. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A
J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081
[TBL] [Abstract][Full Text] [Related]
30. The effect of suramin on laboratory tests of coagulation.
Horne MK; Wilson OJ; Cooper M; Gralnick HR; Myers CE
Thromb Haemost; 1992 Apr; 67(4):434-9. PubMed ID: 1631791
[TBL] [Abstract][Full Text] [Related]
31. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
[TBL] [Abstract][Full Text] [Related]
32. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
Hussain M; Fisher EI; Petrylak DP; O'Connor J; Wood DP; Small EJ; Eisenberger MA; Crawford ED
J Clin Oncol; 2000 Mar; 18(5):1043-9. PubMed ID: 10694555
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
Bitton RJ; Figg WD; Venzon DJ; Dalakas MC; Bowden C; Headlee D; Reed E; Myers CE; Cooper MR
J Clin Oncol; 1995 Sep; 13(9):2223-9. PubMed ID: 7666080
[TBL] [Abstract][Full Text] [Related]
34. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Small EJ; Halabi S; Ratain MJ; Rosner G; Stadler W; Palchak D; Marshall E; Rago R; Hars V; Wilding G; Petrylak D; Vogelzang NJ
J Clin Oncol; 2002 Aug; 20(16):3369-75. PubMed ID: 12177096
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
Ord JJ; Streeter E; Jones A; Le Monnier K; Cranston D; Crew J; Joel SP; Rogers MA; Banks RE; Roberts IS; Harris AL
Br J Cancer; 2005 Jun; 92(12):2140-7. PubMed ID: 15928663
[TBL] [Abstract][Full Text] [Related]
36. Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin.
Hutson PR; Tutsch KD; Rago R; Arzoomanian R; Alberti D; Pomplun M; Church D; Marnocha R; Cheng AL; Kehrli N; Wilding G
Clin Cancer Res; 1998 Jun; 4(6):1429-36. PubMed ID: 9626459
[TBL] [Abstract][Full Text] [Related]
37. Morphohistochemical characterization of suramin--induced chronic toxicity in rat kidney.
Soldani P; Danesi R; Ricciardi MP; Pellegrini A; Natale G; Paparelli A
In Vivo; 1992; 6(6):617-20. PubMed ID: 1296811
[TBL] [Abstract][Full Text] [Related]
38. Postoperative complications in patients receiving suramin therapy.
Cole DJ; Ettinghausen SE; Pass HI; Danforth DN; Linehan MW; Myers CW; Cooper MR; Sindelar WF
Surgery; 1994 Jul; 116(1):90-5. PubMed ID: 8023275
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
Dawson NA; Figg WD; Cooper MR; Sartor O; Bergan RC; Senderowicz AM; Steinberg SM; Tompkins A; Weinberger B; Sausville EA; Reed E; Myers CE
J Clin Oncol; 1997 Apr; 15(4):1470-7. PubMed ID: 9193342
[TBL] [Abstract][Full Text] [Related]
40. Other chemotherapy regimens including mitoxantrone and suramin.
Siu LL; Moore MJ
Semin Urol Oncol; 1997 Feb; 15(1):20-7. PubMed ID: 9050136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
